Locally secreted Fc-OX40L is superior to systemic, antibody mediated, OX40 costimulation for combination immunotherapy
نویسندگان
چکیده
The dramatic clinical success of checkpoint inhibitory therapy (anti-CTLA-4 and anti-PD-1) in a small percentage of patients has highlighted the need to identify combination approaches that may increase the frequency of responders. Two immunotherapy modalities that are proposed to synergize both with each other, and with checkpoint inhibitors are therapeutic vaccines and T cell co-stimulators. To prioritize which T cell costimulators enhance the efficacy of an allogeneic, gp96Ig secreting, cell-based vaccine, we investigated the activity of agonistic antibodies targeting OX40, 4-1BB and ICOS administered together with gp96-Ig vaccines (ImPACT). These data demonstrated that antigen-specific CD8+ T cell expansion is significantly enhanced by OX40,
منابع مشابه
OX40 signaling directly triggers the antitumor effects of NKT cells.
Pathways involving the costimulatory molecule OX40 and OX40 ligand (OX40L) enhance tumor rejection. It was presumed that this effect was mediated by changes in DCs and/or T cells. In this issue of the JCI, Zaini et al. report that, in mice, intratumoral injection of DCs genetically modified to express OX40L suppressed the growth of a preexisting melanoma by directly triggering an antitumor NKT ...
متن کاملAn in vivo immunotherapy screen of costimulatory molecules identifies Fc-OX40L as a potent reagent for the treatment of established murine gliomas.
PURPOSE We tested the combination of a tumor lysate vaccine with a panel of costimulatory molecules to identify an immunotherapeutic approach capable of curing established murine gliomas. EXPERIMENTAL DESIGN Glioma-bearing mice were primed with a tumor lysate vaccine, followed by systemic administration of the following costimulatory ligands: OX40L, CD80, 4-1BBL, and GITRL, which were fused t...
متن کاملherapeutic OX40 Agonist Dynamically Alters Dendritic, othelial, and T Cell Subsets within the Established
Downlo le preclinical modeling currently exists to support the use of OX40 agonists as therapeutic agents in tting of advanced cancers, as well as the mechanisms through which therapeutic efficacy is achieved. ow that treatment of mice bearing well-established day 17 sarcomas with a novel OX40 ligand–Fc protein (OX40L-Fc) resulted in tumor regression or dormancy in the majority of treated anima...
متن کاملCD28-independent costimulation of T cells by OX40 ligand and CD70 on activated B cells.
OX40 and its ligand (OX40L) have been implicated in T cell-dependent humoral immune responses. To further characterize the role of OX40/OX40L in T-B cell interaction, we newly generated an anti-mouse OX40L mAb (RM134L) that can inhibit the costimulatory activity of OX40L transfectants for anti-CD3-stimulated T cell proliferation. Flow cytometric analyses using RM134L and an anti-mouse OX40 mAb ...
متن کاملLigation of OX40 (CD134) regulates graft-versus-host disease (GVHD) and graft rejection in allogeneic bone marrow transplant recipients.
OX40 (CD134) is expressed on activated T cells; its ligand, OX40 ligand (OX40L) is expressed on dendritic cells, B cells, and activated endothelial cells. To determine how OX40-OX40L interaction affects graft-versus-host disease (GVHD), we used antagonistic anti-OX40L monoclonal antibody (mAb) or OX40(-/-) donor or OX40L(-/-) recipient mice. Similar degrees of GVHD reduction were observed with ...
متن کامل